Not true. We are waiting on FDA feed back for CHF.
Regardless of the outcome with the FDA , I see no reason that a partnership would be further delayed.
CLBP is basically ready , we and any other partner would know what is required, if however that partner is also interested in CHF and taking the therapy on for all indications, FDA feedback becomes essential to close a deal.
With this in mind would shorters increase exposure to upside risk?
Ann: MSB Q3 Financial Results and Operational Highlights, page-121
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26808 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 16001 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |